Abstract
The prevalence of prostate cancer emphasizes the need for improved therapeutic options, particularly for metastatic disease. Current treatment includes medical or surgical castration, which initially induces apoptosis of prostate cancer cells, but ultimately an androgen-independent subpopulation emerges. In addition to a transient therapeutic effect, androgen-deprivation therapy (ADT) can initiate biochemical events that may contribute to the development of and progression to an androgen-independent state. This transition involves multiple signal transduction pathways that are accompanied by many biochemical changes resulting from ADT. These molecular events themselves are therapeutic targets and serve as a rationale for adjunctive treatment at the time of ADT.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 82-94 |
| Number of pages | 13 |
| Journal | Nature Clinical Practice Urology |
| Volume | 4 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2007 |
Fingerprint
ASJC Scopus subject areas
- Urology
- Nephrology
Cite this
Biologic agents as adjunctive therapy for prostate cancer : A rationale for use with androgen deprivation. / Nelson, Eric C.; Cambio, Angelo J.; Yang, Joy C.; Lara, Primo N; Evans, Christopher P.
In: Nature Clinical Practice Urology, Vol. 4, No. 2, 02.2007, p. 82-94.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biologic agents as adjunctive therapy for prostate cancer
T2 - A rationale for use with androgen deprivation
AU - Nelson, Eric C.
AU - Cambio, Angelo J.
AU - Yang, Joy C.
AU - Lara, Primo N
AU - Evans, Christopher P
PY - 2007/2
Y1 - 2007/2
N2 - The prevalence of prostate cancer emphasizes the need for improved therapeutic options, particularly for metastatic disease. Current treatment includes medical or surgical castration, which initially induces apoptosis of prostate cancer cells, but ultimately an androgen-independent subpopulation emerges. In addition to a transient therapeutic effect, androgen-deprivation therapy (ADT) can initiate biochemical events that may contribute to the development of and progression to an androgen-independent state. This transition involves multiple signal transduction pathways that are accompanied by many biochemical changes resulting from ADT. These molecular events themselves are therapeutic targets and serve as a rationale for adjunctive treatment at the time of ADT.
AB - The prevalence of prostate cancer emphasizes the need for improved therapeutic options, particularly for metastatic disease. Current treatment includes medical or surgical castration, which initially induces apoptosis of prostate cancer cells, but ultimately an androgen-independent subpopulation emerges. In addition to a transient therapeutic effect, androgen-deprivation therapy (ADT) can initiate biochemical events that may contribute to the development of and progression to an androgen-independent state. This transition involves multiple signal transduction pathways that are accompanied by many biochemical changes resulting from ADT. These molecular events themselves are therapeutic targets and serve as a rationale for adjunctive treatment at the time of ADT.
UR - http://www.scopus.com/inward/record.url?scp=33846958453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846958453&partnerID=8YFLogxK
U2 - 10.1038/ncpuro0700
DO - 10.1038/ncpuro0700
M3 - Article
C2 - 17287869
AN - SCOPUS:33846958453
VL - 4
SP - 82
EP - 94
JO - Nature Reviews Urology
JF - Nature Reviews Urology
SN - 1759-4812
IS - 2
ER -